Lanean...
Pharmacological targeting of PI3K isoforms as a therapeutic strategy in chronic lymphocytic leukaemia
PI3Kδ inhibitors such as idelalisib are providing improved therapeutic options for the treatment of chronic lymphocytic leukaemia (CLL). However under certain conditions, inhibition of a single PI3K isoform can be compensated by the other PI3K isoforms, therefore PI3K inhibitors which target multipl...
Gorde:
| Argitaratua izan da: | Leuk Res Rep |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Elsevier
2015
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4588368/ https://ncbi.nlm.nih.gov/pubmed/26500849 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lrr.2015.09.001 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|